Astrazeneca Share News (AZN)

AstraZeneca posts strong first half despite Covid drug weakness

(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.

IN BRIEF: Astra drug approved while another shows promise

AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

Q2 revenue at $11.23 bln, misses analysts' estimate

*

IN BRIEF: OTAQ names interim finance chief with incumbent to move on

OTAQ PLC - Lancaster, England-based marine technology company, focused on offshore oil and gas industries and aquaculture - Chief Financial Officer Matt Enright resigns effective July 31, to assume a new role outside OTAQ. He was hired as CFO in April 2020. OTAQ appoints Justine Dowds, previously managing director at GB3 Ltd until May, as interim CFO. Dowds was also finance director at Pool Aviation Ltd from 2007 to 2015, and prior to that was financial controller at United Utilities Group PLC and an accountant at AstraZeneca PLC. Enright says: "I believe the company is now well placed to benefit from the investments in resource and products made over the past three years, placing OTAQ on a sound growth path."

Activist investor Elliott takes stake in drug manufacturer Catalent - source

LONDON, July 20 (Reuters) - Activist investor Elliott Investment has taken a stake in contract drugmaker Catalent , a source familiar with the matter told Reuters on Thursday.

AstraZeneca, Sanofi infant respiratory treatment gets US approval

(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.

LONDON BRIEFING: Ocado backs annual guidance as interim loss widens

(Alliance News) - Stocks in London are set to tread water on Tuesday, as investors look ahead to US corporate earnings and economic data.

Rishi Sunak to meet bosses at inaugural Business Council gathering

(Alliance News) - Bosses from AstraZeneca PLC, Alphabet Inc's Google, Shell PLC and other major companies will gather in Downing Street on Tuesday for the first meeting of Rishi Sunak's Business Council.

British prime minister seeks to win back corporate confidence with new business council

LONDON, July 17 (Reuters) - British Prime Minister Rishi Sunak will hold the first meeting of his new business council on Tuesday, in a bid to support his pledge to grow the economy and fend off attempts by the opposition Labour Party to win over the business community.

US FDA approves AstraZeneca and Sanofi's Beyfortus for RSV in infants

(Alliance News) - AstraZeneca PLC and Sanofi SA on Monday said the US Food & Drug Administration has approved the use of Beyfortus, or nirsevimab, in the US.

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

LONDON MARKET OPEN: Stocks mixed ahead of US bank earnings

(Alliance News) - Stock prices in London opened mixed on Friday, after a strong run this week, while investors wait to see how major US banks fared in the second quarter of the year.

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Astra, Daiichi get China approval for Enhertu breast cancer treatment

(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday its metastatic breast cancer treatment with AstraZeneca PLC was approved in China as a monotherapy for adult patients.

LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: